IBC Generium (also known as International Biotechnology Center Generium) has selected Goodwin Biotechnology to access, process and manufacture its immunoglobulin G (IgG)-based, bispecific antibody, GNR-047, to prepare it for testing in early clinical trials it plans to conduct in lymphoma and leukemia patients.
“Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological diseases (blood cancers), such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and different kinds of non-Hodgkin’s lymphoma (NHL), and we were looking to partner with a Contact Manufacturing Organization to help us optimize the process and manufacture material to be used in Phase I clinical trials,” Daniil Talyanskiy, IBC Generium’s chief business officer, said in a press release. “We work with a number of companies around the world to advance our portfolio of drug candidates, and one of our primary collaborators highly recommended Goodwin Biotechnology, based on the track record they had on a number of their projects that Goodwin Biotechnology had worked on over the last six years.”
Goodwin, based in Plantation, Florida, is a biologic development and cGMP manufacturing company specialized in the use of mammalian cell culture (MCC) expression systems and bioconjugation technologies. IBC Generium, based in Russia, is a research company specializing in cell-based technologies.
“Our highly skilled scientists take great pride in working with our clients to enhance the value of their product candidates,” said Soo Young S. Lee, PhD, Goodwin’s chief operating officer. “We are excited to be working on IBC Generium’s cutting edge bispecific antibody, bringing to bear our multiple decades of experience in this field.”